Accelerating Drug Discovery with HyperLab: An Easy-to-Use AI-Driven Platform

HyperLab is an accessible, AI-driven web platform developed by HITS that streamlines the entire structure-based drug discovery workflow through advanced tools for binding prediction, molecular design, and ultra-large-scale screening, achieving high accuracy and rapid experimental validation while significantly lowering the time, cost, and expertise barriers for researchers.

The Gist

Imagine you are trying to find a specific key that fits a very complex, locked door (a disease-causing protein) in a massive, dark warehouse. Traditionally, drug discovery is like hiring a team of thousands of people to physically try every single key in the warehouse, one by one, in the dark. It takes years, costs a fortune, and most keys don't fit.

HyperLab is a new, high-tech "smart flashlight" and "AI Keymaker" developed by a company called HITS. It's designed to help scientists find the right key much faster, cheaper, and without needing to be a master locksmith (a computational expert).

Here is how HyperLab works, broken down into simple parts:

1. The Smart Flashlight (Hyper Binding)

Before you can find a key, you need to see the lock.

• The Problem: Scientists often struggle to predict exactly how a drug molecule will twist and turn to fit into a protein.
• The HyperLab Solution: Think of this as a super-accurate 3D scanner. You tell it the name of the protein, and it instantly figures out exactly how a drug molecule should look to lock into place.
• The Magic: It's so fast and accurate that it rivals the world's most famous AI models (like AlphaFold3) but does the job in minutes instead of hours. It's like having a GPS that tells you exactly which turn to take, rather than guessing.

2. The Infinite Library (Hyper Screening & Screening X)

Now that you know what the lock looks like, you need to find the key.

• Hyper Screening: Imagine a library with 1 million books. HyperLab can read the "spine" of every single book in seconds to find the top 500 that might be the right story. It's fast and efficient.
• Hyper Screening X: This is the real game-changer. Imagine a library with 11 trillion books. No human could ever read them all. HyperLab uses a special "AI imagination" (Generative AI) to not just look at existing books, but to invent new stories that are guaranteed to be interesting. It explores a chemical universe so vast that it finds "needle-in-a-haystack" drugs that traditional methods would never even see.

3. The Master Keymaker (Hyper Design)

Sometimes you find a key that almost works, but the teeth are a little off.

• The Problem: You have a "hit" (a promising drug), but it's not perfect.
• The HyperLab Solution: This is like a 3D printer for molecules. You give it your "almost-right" key, and it automatically reshapes the teeth, adds new grooves, or swaps out parts to make it fit the lock perfectly. It does this while making sure the key is still easy to manufacture (synthesizable) and safe to use.

4. The Safety Inspector (Hyper ADME/T)

Before you hand the key to a patient, you need to make sure it won't break inside the body or cause a fire.

• The HyperLab Solution: This is a virtual safety inspector. It predicts how the drug will behave inside a human body: Will it dissolve? Will it get stuck in the liver? Will it stop the heart from beating? It filters out the dangerous keys before anyone ever has to test them on a real person.

5. The Co-Pilot (AI Assistant)

• The Problem: Drug discovery involves huge amounts of data and complex jargon.
• The HyperLab Solution: Imagine having a tireless, super-smart assistant sitting next to you. You can ask it, "Show me the graph of how well these drugs work," or "Find me all the clinical trials for this molecule," and it does it instantly. It speaks the language of chemistry, so you don't need to be a computer programmer to use it.

The Real-World Proof: A Success Story

The paper shares a story where the team used HyperLab to find a new cancer drug.

• The Old Way: They would have had to test hundreds of thousands of chemicals, taking months and costing millions.
• The HyperLab Way:
  1. They screened a massive list in 24 hours.
  2. They picked just 52 top candidates to test in a lab.
  3. 5 of those worked perfectly (a huge success rate!).
  4. They then used the "Keymaker" (Hyper Design) to tweak the best one, creating a new, even better version that was stronger and safer.

The Bottom Line

HyperLab is like upgrading from a bicycle to a supersonic jet for drug discovery. It takes a process that usually takes years and millions of dollars and compresses it into weeks and a fraction of the cost. It democratizes science, meaning any researcher with a computer can now do "super-computer" level work, bringing life-saving medicines to patients much faster.

Technical Summary

1. Problem Statement

Modern drug discovery faces significant bottlenecks, including:

• High Barriers to Entry: Traditional Structure-Based Drug Discovery (SBDD) requires specialized expertise in computational chemistry and AI, limiting access for experimental researchers.
• Inefficiency: Conventional workflows are fragmented, time-consuming, and costly. High-throughput screening (HTS) often yields low hit rates (low single-digit percentages) and requires testing hundreds of thousands of compounds.
• Computational Limitations: Existing docking tools often struggle with accuracy (especially in pose prediction) and speed, while state-of-the-art models like AlphaFold3 are computationally expensive and slow for large-scale screening.
• Chemical Space Exploration: Traditional virtual screening is limited to libraries of ~1 million compounds, missing vast regions of chemical space where novel active compounds may exist.

2. Methodology: The HyperLab Platform

HyperLab is a web-based, integrated AI platform developed by HITS to streamline the entire drug discovery pipeline. It employs a Structure-Based Drug Discovery (SBDD) approach with the following core modules:

• Hyper Binding (Pose & Affinity Prediction):
  • Uses a physics-informed deep learning model to predict protein-ligand binding poses and affinities.
  • Co-folding Capability: Can predict complex structures directly from protein sequences (using UniProt IDs) without requiring pre-existing 3D structures, eliminating the need for PDB selection.
  • Supports both rigid docking and covalent binding prediction (Auto-Recommendation and Manual Definition modes).
• Hyper Screening & Hyper Screening X:
  • Hyper Screening: Virtual screening of pre-processed libraries (up to 1 million compounds) including FDA-approved drugs, natural products, and diverse fragments.
  • Hyper Screening X: Utilizes Generative AI (GFlowNet-based deep learning) to explore a virtual library of 11 trillion molecules. It optimizes for binding scores and specific properties (MW, LogP, TPSA) simultaneously, offering a hit discovery probability dozens of times higher than traditional methods.
• Hyper Design (Lead Optimization):
  • An AI-driven module for scaffold hopping and fragment growth. It generates novel derivatives by modifying specific substructures while maintaining covalent bonds or key interactions.
  • Considers synthesizability (using fragments from ChEMBL) and provides 3D visualizations for iterative design.
• Hyper ADME/T: Predicts 19 key pharmacological properties (e.g., solubility, CYP inhibition, hERG, BBB penetration) to filter candidates early.
• SAR Analysis & AI Assistant:
  • SAR Module: Automates R-group decomposition and hierarchical analysis to visualize structure-activity relationships.
  • AI Assistant: A specialized agent (powered by Claude 3.7) that integrates with drug databases (PubChem, ChEMBL, PDB), performs coding tasks, and guides users through the workflow.

3. Key Contributions

• Democratization of AI: Provides an intuitive UI/UX allowing non-computational researchers to perform advanced SBDD tasks without coding or specialized knowledge.
• Unified Workflow: Integrates hit identification, virtual screening, lead optimization, and ADMET prediction into a single cohesive environment, reducing workflow fragmentation.
• Massive Scale Exploration: The introduction of Hyper Screening X allows for the exploration of 11 trillion molecules, a scale previously inaccessible to standard virtual screening.
• Covalent Drug Discovery: A dedicated, streamlined workflow for covalent inhibitors, including automated warhead-residue pairing and covalent docking.
• Speed vs. Accuracy Trade-off: Offers a solution that approaches the accuracy of AlphaFold3 but with a 5-fold speed advantage (3 minutes vs. 15 minutes per complex on comparable hardware).

4. Results

Benchmark Performance

• Pose Prediction (PoseBuster v2):
  • Hyper Binding (with binding site info): 77% accuracy, surpassing Diffdock (13%), Vina (58%), and Chai Discovery (66%).
  • Comparison: Closely approaches AlphaFold3 (84%) and Boltz2 (78%) but is significantly faster.
  • Co-folding (Sequence only): Achieved 68% accuracy without using 3D structural inputs, demonstrating robust generalization.
• Binding Affinity Prediction (FEP Datasets):
  • Outperformed both deep learning models (Luminet, Genscore) and physics-based docking (Glide SP, Vina).
  • FEP Dataset 1: Pearson correlation of 0.70 (vs. 0.65 for Luminet).
  • FEP Dataset 2: Pearson correlation of 0.53 (vs. 0.52 for Genscore).
• Covalent Docking:
  • Pose Accuracy: Covalent Hyper Binding (co-folding) achieved 88.7%, significantly outperforming COV SMINA (48.4%) and GNINA (46.8%).
  • Enrichment Factor (EF@10%): For KRAS, Hyper Binding achieved an EF of 9.97, compared to 3.32 for COV SMINA and 0.00 for GNINA.

Experimental Validation (Case Study)

• Screening Efficiency: Identified 5 active compounds from 52 candidates (Hit rate: ~9.6%) within 24 hours, compared to standard HTS hit rates of <1%.
• Potency:
  • Initial hits showed IC50 values ranging from 70 to 600 nM.
  • Hyper Design generated novel derivatives; 3 out of 5 synthesized compounds showed >75% inhibition at 1 µM (IC50: 200–400 nM).
  • One derivative (H00505) showed activity comparable or superior to the reference compound and successfully activated the antioxidant response pathway (ARE luciferase assay).
• Resource Reduction: The computational triage reduced the required experimental wells from ~200,000 (standard HTS) to just 100 wells.

5. Significance

HyperLab represents a transformative step in pharmaceutical research by:

1. Lowering Barriers: Making high-level AI drug discovery accessible to experimentalists, reducing reliance on specialized computational teams.
2. Accelerating Timelines: Compressing the "Hit-to-Lead" phase from months to days (e.g., 24-hour screening cycle).
3. Cost Efficiency: Drastically reducing the cost of experimental validation by prioritizing high-probability candidates via AI, minimizing wasted resources on inactive compounds.
4. Expanding Chemical Space: Enabling the discovery of novel chemotypes through the exploration of trillion-scale virtual libraries, moving beyond the limitations of existing commercial libraries.

The platform successfully bridges the gap between theoretical AI capabilities and practical, experimental drug discovery, validating its utility in generating nanomolar-potency leads with structural novelty.